Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that you inject subcutaneously once every seven days
The tirzepatide eye disease risk they warned about does not hold up the data point to less retinopathy, not more
That said, if you need the medication for medical reasons such as diabetes, the benefits may outweigh the risks and that decision should always be made with your healthcare provider
For cagrilintide, readers may see trial references, research-peptide marketing, or forum posts
Scientists have discosvered that synovial tissues show evidence of GLP-1 along with its related activities, which function as internal modulators for three different processes that include joint inflammation and tissue restoration
Will I regain the weight if I stop the medication